These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

352 related articles for article (PubMed ID: 36197593)

  • 1. Antibody-Drug Conjugates in Non-Small Cell Lung Cancer: Emergence of a Novel Therapeutic Class.
    Marks JA; Wilgucki M; Liu SV; Reuss JE
    Curr Oncol Rep; 2022 Dec; 24(12):1829-1841. PubMed ID: 36197593
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TROP-2 directed antibody-drug conjugates (ADCs): The revolution of smart drug delivery in advanced non-small cell lung cancer (NSCLC).
    Parisi C; Mahjoubi L; Gazzah A; Barlesi F
    Cancer Treat Rev; 2023 Jul; 118():102572. PubMed ID: 37230055
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibody drug conjugates in non-small cell lung cancer: An emerging therapeutic approach.
    Marks S; Naidoo J
    Lung Cancer; 2022 Jan; 163():59-68. PubMed ID: 34923203
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 'Targeting' Improved Outcomes with Antibody-Drug Conjugates in Non-Small Cell Lung Cancer-An Updated Review.
    Verma S; Breadner D; Raphael J
    Curr Oncol; 2023 Apr; 30(4):4329-4350. PubMed ID: 37185443
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comprehensive review on antibody-drug conjugates (ADCs) in the treatment landscape of non-small cell lung cancer (NSCLC).
    Abuhelwa Z; Alloghbi A; Nagasaka M
    Cancer Treat Rev; 2022 May; 106():102393. PubMed ID: 35472631
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antibody-drug conjugates: A promising novel therapeutic approach in lung cancer.
    Desai A; Abdayem P; Adjei AA; Planchard D
    Lung Cancer; 2022 Jan; 163():96-106. PubMed ID: 34942494
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibody-Drug Conjugates as Novel Therapeutic Agents for Non-Small Cell Lung Carcinoma with or without Alterations in Oncogenic Drivers.
    Somme LB; Chouaid C; Moinard-Butot F; Barbe-Richaud JB; Greillier L; Schott R
    BioDrugs; 2024 Jul; 38(4):487-497. PubMed ID: 38767823
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antibody Drug Conjugates in Lung Cancer.
    Merle G; Friedlaender A; Desai A; Addeo A
    Cancer J; 2022 Nov-Dec 01; 28(6):429-435. PubMed ID: 36383905
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibody Drug Conjugates in Lung Cancer: State of the Current Therapeutic Landscape and Future Developments.
    Reuss JE; Gosa L; Liu SV
    Clin Lung Cancer; 2021 Nov; 22(6):483-499. PubMed ID: 34420859
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Implementing antibody-drug conjugates (ADCs) in HER2-positive breast cancer: state of the art and future directions.
    Ferraro E; Drago JZ; Modi S
    Breast Cancer Res; 2021 Aug; 23(1):84. PubMed ID: 34380530
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pioneering the Way: The Revolutionary Potential of Antibody-Drug Conjugates in NSCLC.
    Chen X; Zeng C
    Curr Treat Options Oncol; 2024 Apr; 25(4):556-584. PubMed ID: 38520605
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The clinical development of antibody-drug conjugates for non-small cell lung cancer therapy.
    Liu X; Deng J; Zhang R; Xing J; Wu Y; Chen W; Liang B; Xing D; Xu J; Zhang M
    Front Immunol; 2023; 14():1335252. PubMed ID: 38162667
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibody-drug conjugates in advanced lung cancer: Is this a new frontier?
    Reuss JE; Rosner S; Levy BP
    Clin Adv Hematol Oncol; 2024 Jun; 22(5):217-226. PubMed ID: 38805313
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antibody-drug conjugates for non-small cell lung cancer: Advantages and challenges in clinical translation.
    Zhao C; Zhang R; Yang H; Gao Y; Zou Y; Zhang X
    Biochem Pharmacol; 2024 Aug; 226():116378. PubMed ID: 38908529
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The target invites a foe: antibody-drug conjugates in gynecologic oncology.
    Campos MP; Konecny GE
    Curr Opin Obstet Gynecol; 2018 Feb; 30(1):44-50. PubMed ID: 29227302
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibody-Drug Conjugates for Lung Cancer: Payloads and Progress.
    Rosner S; Valdivia A; Hoe HJ; Murray JC; Levy B; Felip E; Solomon BJ
    Am Soc Clin Oncol Educ Book; 2023 May; 43():e389968. PubMed ID: 37163707
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel antibody-drug conjugate, HcHAb18-DM1, has potent anti-tumor activity against human non-small cell lung cancer.
    Huhe M; Lou J; Zhu Y; Zhao Y; Shi Y; Wang B; Sun X; Zhang X; Zhang Y; Chen ZN
    Biochem Biophys Res Commun; 2019 Jun; 513(4):1083-1091. PubMed ID: 31010682
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Research Progress of Antibody-drug Conjugates in Advanced Non-small Cell Lung Cancer].
    Wang N; Zhao L; Zhang D; Jia Y; Kong F
    Zhongguo Fei Ai Za Zhi; 2022 Mar; 25(3):214-218. PubMed ID: 35340165
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antibody-drug conjugates in lung and breast cancer: current evidence and future directions-a position statement from the ETOP IBCSG Partners Foundation.
    Peters S; Loi S; André F; Chandarlapaty S; Felip E; Finn SP; Jänne PA; Kerr KM; Munzone E; Passaro A; Pérol M; Smit EF; Swanton C; Viale G; Stahel RA
    Ann Oncol; 2024 Jul; 35(7):607-629. PubMed ID: 38648979
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibody-Drug Conjugates in Lung Cancer: Recent Advances and Implementing Strategies.
    Passaro A; Jänne PA; Peters S
    J Clin Oncol; 2023 Jul; 41(21):3747-3761. PubMed ID: 37224424
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.